Red Light Holland Expands Global Clinical Network via Filament Health Acquisition

Red Light Holland has announced a significant expansion of Filament Health's clinical network through three new licensing agreements signed in March 2026. This strategic growth includes the completion of two research shipments to prominent institutions across Australia, the United Kingdom, and Canada, bolstering the global footprint of the PEX010 drug candidate. These developments follow Red Light Holland's entry into a definitive arrangement agreement to acquire Filament Health and its extensive patent portfolio. The expansion is designed to accelerate global clinical trials for botanical psilocybin-based treatments ahead of the merger's completion. Analysts view these international milestones as a validation of the strategic synergy between the two companies and their clinical pipeline. This progress underscores Red Light Holland's commitment to advancing its pharmaceutical capabilities and securing a leading position in the biotech sector.